INmune Bio, Inc. (INMB) is a Biotechnology company in the Healthcare sector, currently trading at $1.26. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is INMB = $22 (+1646% upside).
Valuation: INMB trades at a trailing Price-to-Earnings (P/E) of -0.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.1.
Financials: revenue is $50,000, +35.9%/yr average growth. Net income is $46M (loss), growing at -19.8%/yr. Net profit margin is -91866% (negative). Gross margin is 100% (+0 pp trend).
Balance sheet: total debt is $1M against $24M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 3.55 (strong liquidity). Debt-to-assets is 3.2%. Total assets: $32M.
Analyst outlook: 6 / 9 analysts rate INMB as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 73/100 (Pass), Income 10/100 (Fail).
